Document is current
Any future updates will be listed below
-
Authors
Téblick, Laura
Lipovac, Marijana
Burdier, F. Ricardo
De Smet, Annemie
Bell, Margo
van den Borst, Eef
Matheeussen, Veerle
Vorsters, Alex
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (11PJK24N, 1SC9123N)
Universiteit Antwerpen (44754)
Merck (59401)
European Research Council (101040588)
- License Information
-
More Information
Article History
Received: 3 January 2024
Accepted: 8 February 2024
First Online: 17 February 2024
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of UZA/University of Antwerp (B300201734129). Informed consent was obtained from all subjects involved in the study.
: A.V. is a co-founder and former board member of Novosanis (Subsidiary of OraSure Technologies Inc, Wijnegem, Belgium), a spin-off company of the University of Antwerp, and was a minority shareholder until January 2019. The University of Antwerp received grants from Merck, GSK, Hologic, Abbott, Roche, and Cepheid to support the HPV Prevention and Control Board. The University of Antwerp received a project grant and honoraria fee for lectures, presentations, and speaker bureaus from Merck. Other authors declare that they have no conflict of interest.
